Elucida Oncology develops targeted CDot Drug Conjugates (CDCs) to deliver precise therapeutic agents directly to primary solid tumors and metastatic cancer cells. This approach enhances treatment efficacy while minimizing damage to surrounding healthy tissue, addressing the need for more effective cancer therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer treatments lack precision, leading to damage of healthy tissues alongside cancerous cells, resulting in significant side effects and reduced quality of life for patients. Traditional chemotherapy and radiation often affect the entire body, limiting the dosage that can be safely administered and hindering treatment effectiveness.
Solution
Elucida Oncology is developing CDot Drug Conjugates (CDCs) that selectively target and deliver therapeutic agents directly to primary solid tumors and metastatic cancer cells. This targeted approach aims to enhance treatment efficacy by concentrating the drug's effect on cancerous tissue while minimizing exposure and damage to surrounding healthy tissue. By precisely targeting cancer cells, CDCs have the potential to reduce the systemic toxicity associated with conventional cancer therapies, leading to improved patient outcomes and reduced side effects. The technology seeks to improve the therapeutic window for cancer drugs, allowing for higher doses to be administered directly to the tumor site.
Target Audience
The primary target audience includes oncology researchers, pharmaceutical companies, and ultimately, cancer patients seeking more effective and less toxic treatment options for solid tumors and metastatic cancers.
Features
- CDot nanoparticles engineered for targeted delivery to specific cancer cell markers
- Conjugation chemistry that links potent anti-cancer drugs to the CDot carrier
- Controlled drug release mechanisms to ensure payload delivery within the tumor microenvironment
- Enhanced permeability and retention (EPR) effect for improved tumor accumulation
- Real-time imaging capabilities to track drug distribution and treatment response